{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:46:42Z","timestamp":1756464402840},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1208\/s12248-021-00640-7","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T16:26:19Z","timestamp":1633710379000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cluster Gauss\u2013Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics"],"prefix":"10.1208","volume":"23","author":[{"given":"Jin","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"12","key":"640_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1177\/0037549703040943","volume":"79","author":"KH Cho","year":"2003","unstructured":"Cho KH, Shin SY, Kolch W, Wolkenhauer O. Experimental design in systems biology, based on parameter sensitivity analysis using a Monte Carlo method: a case study for the TNF alpha-mediated NF-kappa B signal transduction pathway. Simul-T Soc Mod Sim. 2003;79(12):726\u201339. https:\/\/doi.org\/10.1177\/0037549703040943.","journal-title":"Simul-T Soc Mod Sim"},{"issue":"5","key":"640_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.febslet.2005.01.009","volume":"579","author":"ZK Zi","year":"2005","unstructured":"Zi ZK, Cho KH, Sung MH, Xia XF, Zheng JS, Sun ZR. In silico identification of the key components and steps in IFN-gamma induced JAK-STAT signaling pathway. FEBS Lett. 2005;579(5):1101\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2005.01.009.","journal-title":"FEBS Lett"},{"key":"640_CR3","doi-asserted-by":"publisher","unstructured":"Frohlich F, Kessler T, Weindl D, Shadrin A, Schmiester L, Hache H, et al. Efficient parameter estimation enables the prediction of drug response using a mechanistic pan-cancer pathway model. Cell Systems. 2018;7(6):567-+.\u00a0https:\/\/doi.org\/10.1016\/j.cels.2018.10.013.","DOI":"10.1016\/j.cels.2018.10.013"},{"key":"640_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1752-0509-3-98","volume":"3","author":"DM Wittmann","year":"2009","unstructured":"Wittmann DM, Krumsiek J, Saez-Rodriguez J, Lauffenburger DA, Klamt S, Theis FJ. Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling. BMC Syst Biol. 2009;3:98. https:\/\/doi.org\/10.1186\/1752-0509-3-98.","journal-title":"BMC Syst Biol"},{"issue":"1","key":"640_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1109\/Tcbb.2011.63","volume":"9","author":"JY Sun","year":"2012","unstructured":"Sun JY, Garibaldi JM, Hodgman C. Parameter estimation using metaheuristics in systems biology: a comprehensive review. Ieee Acm T Comput Bi. 2012;9(1):185\u2013202. https:\/\/doi.org\/10.1109\/Tcbb.2011.63.","journal-title":"Ieee Acm T Comput Bi"},{"key":"640_CR6","unstructured":"Aoki Y, Hayami K, Toshimoto K, Sugiyama Y. Cluster Gauss-Newton method for sampling multiple solutions of nonlinear least squares problems - with applications to pharmacokinetic models. arXiv:180806714 [mathNA]. 2018."},{"key":"640_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1752-0509-6-133","volume":"6","author":"C Terfve","year":"2012","unstructured":"Terfve C, Cokelaer T, Henriques D, MacNamara A, Goncalves E, Morris MK, et al. CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. BMC Syst Biol. 2012;6:133. https:\/\/doi.org\/10.1186\/1752-0509-6-133.","journal-title":"BMC Syst Biol"},{"issue":"1","key":"640_CR8","doi-asserted-by":"publisher","first-page":"B14","DOI":"10.1137\/120885462","volume":"36","author":"Y Aoki","year":"2014","unstructured":"Aoki Y, Hayami K, De Sterck H, Konagaya A. Cluster Newton method for sampling multiple solutions of underdetermined inverse problems: application to a parameter identification problem in pharmacokinetics. Siam J Sci Comput. 2014;36(1):B14\u201344. https:\/\/doi.org\/10.1137\/120885462.","journal-title":"Siam J Sci Comput"},{"key":"640_CR9","doi-asserted-by":"publisher","unstructured":"Asami S, Kiga D, Konagaya A. Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model. Bmc Systems Biology. 2017;11. ARTN 129. https:\/\/doi.org\/10.1186\/s12918-017-0513-2.","DOI":"10.1186\/s12918-017-0513-2"},{"key":"640_CR10","doi-asserted-by":"publisher","unstructured":"Terfve C, Cokelaer T, Henriques D, MacNamara A, Goncalves E, Morris MK, et al. CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. Bmc Syst Biol. 2012;6. doi: Artn 133. https:\/\/doi.org\/10.1186\/1752-0509-6-133.","DOI":"10.1186\/1752-0509-6-133"},{"issue":"8","key":"640_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/psp4.12225","volume":"6","author":"P Traynard","year":"2017","unstructured":"Traynard P, Tobalina L, Eduati F, Calzone L, Saez-Rodriguez J. Logic Modeling in quantitative systems pharmacology. Cpt-Pharmacomet Syst. 2017;6(8):499\u2013511. https:\/\/doi.org\/10.1002\/psp4.12225.","journal-title":"Cpt-Pharmacomet Syst"},{"key":"640_CR12","unstructured":"Nanavati C. Pharmacodynamic systems analysis of HDAC and proteasome inhibition in multiple myeloma. PhD Dissertation, SUNY at Buffalo. 2016."},{"issue":"11","key":"640_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/psp4.12246","volume":"6","author":"C Nanavati","year":"2017","unstructured":"Nanavati C, Ruszaj D, Mager DE. Cell signaling model connects vorinostat pharmacokinetics and tumor growth response in multiple myeloma xenografts. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):756\u201364. https:\/\/doi.org\/10.1002\/psp4.12246.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"640_CR14","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"VM Richon","year":"2006","unstructured":"Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Brit J Cancer. 2006;95:S2\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6603463.","journal-title":"Brit J Cancer"},{"issue":"11","key":"640_CR15","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1535-7163.Mct-11-0745","volume":"10","author":"B Piperdi","year":"2011","unstructured":"Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R. Bortezomib: understanding the mechanism of action. Mol Cancer Ther. 2011;10(11):2029\u201330. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0745.","journal-title":"Mol Cancer Ther"},{"key":"640_CR16","doi-asserted-by":"publisher","unstructured":"Krumsiek J, Polsterl S, Wittmann DM, Theis FJ. Odefy - from discrete to continuous models. Bmc Bioinformatics. 2010;11. Artn 233. https:\/\/doi.org\/10.1186\/1471-2105-11-233.","DOI":"10.1186\/1471-2105-11-233"},{"issue":"1","key":"640_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10928-017-9567-4","volume":"45","author":"P Bloomingdale","year":"2018","unstructured":"Bloomingdale P, Nguyen VA, Niu J, Mager DE. Boolean network modeling in systems pharmacology. J Pharmacokinet Pharmacodyn. 2018;45(1):159\u201380. https:\/\/doi.org\/10.1007\/s10928-017-9567-4.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"640_CR18","doi-asserted-by":"publisher","unstructured":"Egea JA, Balsa-Canto E, Garc\u00eda M-SG, Banga JR. Dynamic optimization of nonlinear processes with an enhanced scatter search method. Industrial & Engineering Chemistry Research. 2009;48(9):4388\u2013401. https:\/\/doi.org\/10.1021\/ie801717t.","DOI":"10.1021\/ie801717t"},{"issue":"6","key":"640_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1049\/iet-syb.2011.0015","volume":"5","author":"Z Zi","year":"2011","unstructured":"Zi Z. Sensitivity analysis approaches applied to systems biology models. IET Syst Biol. 2011;5(6):336\u201346. https:\/\/doi.org\/10.1049\/iet-syb.2011.0015.","journal-title":"IET Syst Biol"},{"issue":"1\u20133","key":"640_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0378-4754(00)00270-6","volume":"55","author":"IM Sobol","year":"2001","unstructured":"Sobol IM. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. Math Comput Simulat. 2001;55(1\u20133):271\u201380. https:\/\/doi.org\/10.1016\/S0378-4754(00)00270-6.","journal-title":"Math Comput Simulat"},{"issue":"48","key":"640_CR21","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.1038\/onc.2008.297","volume":"27","author":"J Li","year":"2008","unstructured":"Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48):6194\u2013206. https:\/\/doi.org\/10.1038\/onc.2008.297.","journal-title":"Oncogene"},{"issue":"8","key":"640_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/psp4.12206","volume":"6","author":"B Ribba","year":"2017","unstructured":"Ribba B, Grimm HP, Agoram B, Davies MR, Gadkar K, Niederer S, et al. Methodologies for quantitative systems pharmacology (QSP) models: design and estimation. CPT Pharmacometrics Syst Pharmacol. 2017;6(8):496\u20138. https:\/\/doi.org\/10.1002\/psp4.12206.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"640_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.306","volume":"4","author":"GM Matthews","year":"2013","unstructured":"Matthews GM, Lefebure M, Doyle MA, Shortt J, Ellul J, Chesi M, et al. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL\/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis. 2013;4: e798. https:\/\/doi.org\/10.1038\/cddis.2013.306.","journal-title":"Cell Death Dis"},{"issue":"3","key":"640_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s11095-017-2095-5","volume":"34","author":"C Nanavati","year":"2017","unstructured":"Nanavati C, Mager DE. Sequential exposure of bortezomib and vorinostat is synergistic in multiple myeloma cells. Pharm Res. 2017;34(3):668\u201379. https:\/\/doi.org\/10.1007\/s11095-017-2095-5.","journal-title":"Pharm Res"},{"issue":"10","key":"640_CR25","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1371\/journal.pcbi.0030189","volume":"3","author":"RN Gutenkunst","year":"2007","unstructured":"Gutenkunst RN, Waterfall JJ, Casey FP, Brown KS, Myers CR, Sethna JP. Universally sloppy parameter sensitivities in systems biology models. PLoS Comput Biol. 2007;3(10):1871\u20138. https:\/\/doi.org\/10.1371\/journal.pcbi.0030189.","journal-title":"PLoS Comput Biol"},{"issue":"18","key":"640_CR26","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/bioinformatics\/bts363","volume":"28","author":"F Eduati","year":"2012","unstructured":"Eduati F, De Las RJ, Di Camillo B, Toffolo G, Saez-Rodriguez J. Integrating literature-constrained and data-driven inference of signalling networks. Bioinformatics. 2012;28(18):2311\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/bts363.","journal-title":"Bioinformatics"},{"key":"640_CR27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0078","author":"F Eduati","year":"2017","unstructured":"Eduati F, Doldan-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F, et al. Drug resistance mechanisms in colorectal cancer dissected with cell type-specific dynamic logic models. Cancer Res. 2017. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0078.","journal-title":"Cancer Res"},{"issue":"1","key":"640_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/leu.2011.310","volume":"26","author":"B Mohty","year":"2012","unstructured":"Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment\u2019 approaches in the era of novel agents. Leukemia. 2012;26(1):73\u201385. https:\/\/doi.org\/10.1038\/leu.2011.310.","journal-title":"Leukemia"},{"issue":"21","key":"640_CR29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood.V116.21.3046.3046","volume":"116","author":"B Heeg","year":"2010","unstructured":"Heeg B, van Agthoven M, Liwing J, Mellqvist UH, Plesner T, Logman F, et al. Optimal treatment sequencing in multiple myeloma: an exploratory modeling approach. Blood. 2010;116(21):1255\u20136. https:\/\/doi.org\/10.1182\/blood.V116.21.3046.3046.","journal-title":"Blood"},{"key":"640_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/msb.2008.74","volume":"5","author":"WW Chen","year":"2009","unstructured":"Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, et al. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol. 2009;5:239. https:\/\/doi.org\/10.1038\/msb.2008.74.","journal-title":"Mol Syst Biol"},{"issue":"4","key":"640_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejps.2011.10.026","volume":"46","author":"G Lebedeva","year":"2012","unstructured":"Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, et al. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2\/3 network. Eur J Pharm Sci. 2012;46(4):244\u201358. https:\/\/doi.org\/10.1016\/j.ejps.2011.10.026.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"640_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120007","volume":"10","author":"J Poleszczuk","year":"2015","unstructured":"Poleszczuk J, Hahnfeldt P, Enderling H. Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS ONE. 2015;10(3): e0120007. https:\/\/doi.org\/10.1371\/journal.pone.0120007.","journal-title":"PLoS ONE"},{"key":"640_CR33","doi-asserted-by":"publisher","unstructured":"Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009;2(77):ra31. https:\/\/doi.org\/10.1126\/scisignal.2000352.","DOI":"10.1126\/scisignal.2000352"},{"issue":"2","key":"640_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/psp4.6","volume":"4","author":"XY Zhang","year":"2015","unstructured":"Zhang XY, Trame MN, Lesko LJ, Schmidt S. Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):69\u201379. https:\/\/doi.org\/10.1002\/psp4.6.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"640_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1049\/iet-syb.2011.0015","volume":"5","author":"Z Zi","year":"2011","unstructured":"Zi Z. Sensitivity analysis approaches applied to systems biology models. Iet Syst Biol. 2011;5(6):336\u201346. https:\/\/doi.org\/10.1049\/iet-syb.2011.0015.","journal-title":"Iet Syst Biol"},{"issue":"10","key":"640_CR36","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1210\/jc.2005-2472","volume":"91","author":"CS Mitsiades","year":"2006","unstructured":"Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocr Metab. 2006;91(10):4013\u201321. https:\/\/doi.org\/10.1210\/jc.2005-2472.","journal-title":"J Clin Endocr Metab"},{"key":"640_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/Dddt.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Dev Ther. 2016;10:217\u201326. https:\/\/doi.org\/10.2147\/Dddt.S93602.","journal-title":"Drug Des Dev Ther"},{"issue":"16","key":"640_CR38","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.Ccr-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311\u201321. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0476.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"640_CR39","first-page":"93","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41(2):93\u2013141.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"640_CR40","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/cpt.1434","volume":"105","author":"J Niu","year":"2019","unstructured":"Niu J, Straubinger RM, Mager DE. Pharmacodynamic drug\u2013drug interactions. Clin Pharmacol Ther. 2019;105(6):1395\u2013406. https:\/\/doi.org\/10.1002\/cpt.1434.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"640_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/psp4.12358","volume":"8","author":"V Ramakrishnan","year":"2019","unstructured":"Ramakrishnan V, Mager DE. Pharmacodynamic models of differential bortezomib signaling across several cell lines of multiple myeloma. Cpt-Pharmacomet Syst. 2019;8(3):146\u201357. https:\/\/doi.org\/10.1002\/psp4.12358.","journal-title":"Cpt-Pharmacomet Syst"},{"issue":"2","key":"640_CR42","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20188664","volume":"16","author":"F Eduati","year":"2020","unstructured":"Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, et al. Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Mol Syst Biol. 2020;16(2): e8664. https:\/\/doi.org\/10.15252\/msb.20188664.","journal-title":"Mol Syst Biol"},{"key":"640_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa561","author":"E Gjerga","year":"2020","unstructured":"Gjerga E, Trairatphisan P, Gabor A, Koch H, Chevalier C, Ceccarelli F, et al. Converting networks to predictive logic models from perturbation signalling data with CellNOpt. Bioinformatics. 2020. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa561.","journal-title":"Bioinformatics"},{"issue":"8","key":"640_CR44","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1091\/mbc.e03-11-0794","volume":"15","author":"KC Chen","year":"2004","unstructured":"Chen KC, Calzone L, Csikasz-Nagy A, Cross FR, Novak B, Tyson JJ. Integrative analysis of cell cycle control in budding yeast. Mol Biol Cell. 2004;15(8):3841\u201362. https:\/\/doi.org\/10.1091\/mbc.e03-11-0794.","journal-title":"Mol Biol Cell"},{"issue":"6","key":"640_CR45","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1046\/j.1432-1327.2000.01197.x","volume":"267","author":"BN Kholodenko","year":"2000","unstructured":"Kholodenko BN. Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. Eur J Biochem. 2000;267(6):1583\u20138. https:\/\/doi.org\/10.1046\/j.1432-1327.2000.01197.x.","journal-title":"Eur J Biochem"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00640-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T18:24:54Z","timestamp":1638210294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00640-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00640-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"110"}}